Breakthrough Therapy Designation for Encorafenib, Binimetinib, Cetuximab in BRAFV600E-Mutant CRC

Share this content:
Results from a safety lead-in phase conducted prior to a phase 3 trial examining the safety and tolerability of encorafenib, binimetinib, and cetuximab in combination led the FDA to assign the regimen
Results from a safety lead-in phase conducted prior to a phase 3 trial examining the safety and tolerability of encorafenib, binimetinib, and cetuximab in combination led the FDA to assign the regimen

The US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to the combination regimen of encorafenib, binimetinib, and cetuximab for the treatment of patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) who have failed 1 to 2 previous lines of therapy, according to a press release.1

Patients with BRAFV600E-mutant mCRC have nearly a twofold risk of death compared with patients with wild-type BRAF disease. There are no FDA-approved therapies for this patient population.

The FDA based its decision on data from the safety lead-in of the BEACON CRC phase 3 (ClinicalTrials.gov Identifier: NCT02928224) study, for which researchers enrolled 30 patients to receive encorafenib 300 mg once daily, binimetinib 45 mg twice daily, plus cetuximab 400 mg/m2 initial dose then 250 mg/m2 once weekly.

Results showed that the 1-year overall survival (OS) rate was 62%, but the median OS had not been reached. At the time of analysis, the OS data were fully mature through 12 months. The median progression-free survival (PFS) was 8 months (95% CI, 5.6-9.3), and was comparable between patients who received 1 and 2 previous lines of therapy.

The confirmed overall response rate (ORR) was 48%, and patients who had only received 1 previous line of therapy had an ORR of 62%.

The most frequently occurring grade 3 to 4 adverse events (AE) included fatigue, anemia, increased blood creatinine kinase, and increased aspartate aminotransferase; no new safety signals were reported and AEs were consistent with those previously observed.

Encorafenib, binimetinib, plus cetuximab is an investigational therapeutic regimen and has not yet been approved by the FDA.

Reference

  1. Array BioPharma receives FDA Breakthrough Therapy Designation for BRAFTOVI™ in combination with MEKTOVI® and cetuximab for BRAFV600E-mutant metastatic colorectal cancer [press release]. Boulder, CO: PR Newswire; August 7, 2018. https://markets.businessinsider.com/news/stocks/array-biopharma-receives-fda-breakthrough-therapy-designation-for-braftovi-in-combination-with-mektovi-and-cetuximab-for-brafv600e-mutant-metastatic-colorectal-cancer-1027437791. Accessed August 7, 2018.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs